Reportlinker Adds Botanical and Plant-Derived Drugs: Global Mark...(CLAIMER CHAPTER 2: SUMM...),Health

CHAPTER 2: SUMMARY

SUMMARY TABLE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

SUMMARY FIGURE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

CHAPTER 3: OVERVIEW

BRIEF HISTORY OF PLANT-DERIVED MEDICINES

BRIEF HISTORY OF PLANT-. . . (CONTINUED)

TABLE 2 KEY DATES IN BOTANICAL MEDICINE

TABLE 3 WELL KNOWN PLANT-DERIVED DRUGS

OPPORTUNITY LIES BEYOND WHAT'S KNOWN

FIGURE 1 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S. (2000-2005)* (%)

KEY DRIVERS

KEY CHALLENGES

SIGNS OF INDUSTRY INVESTMENT

TABLE 4 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT

TABLE 5 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS

BOTANICAL DRUGS DEFINED

UNDERSTANDING THE REGULATORY PROCESS

TABLE 6 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY

THE FIRST APPROVED BOTANICAL

A GROWING PIPELINE

FIGURE 2 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER)

OVERALL PHARMA LANDSCAPE

TABLE 7 TOP PHARMA COMPANIES BY REVENUE, 2007 ($ BILLIONS)

MAJOR CLASSES OF PLANT DRUGS

Terpenes and Steroids

Terpenes

Steroids

Alkaloids and Glycosides

Alkaloids

Ergot Alkaloids

Morphine Alkaloids

Vinca Alkaloids

Glycosides

Cardiac Glycosides

Anthraglycosides

Phenols

E. Cava Algae

Flavonoids

Resveratrol

Coumarin

Catechins

Proanthocyanidins

INTELLECTUAL PROPERTY

PRODUCTION

MO
'/>"/>